Synthesis and evaluation of antiproliferative activity of substituted N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamides

TETRAHEDRON LETTERS

卷:55

Article

Motavallizadeh, Somayeh^1,2  Fallah-Tafti, Asal^1,2  Maleki, Saeedeh^1,2  Shirazi, Amir Nasrolahi⁴  Pordeli, Mahboobeh³  Safavi, Maliheh³  Ardestani, Sussan Kabudanian³  Asd, Shaaban⁴  Tiwari, Rakesh^4,5  Oh, Donghoon⁴  Shafiee, Abbas^1,2  Foroumadi, Alireza^1,2  Parang, Keykavous^4,5  Akbarzadeh, Tahmineh^1,2 

[1] Univ Tehran Med Sci, Fac Pharm, Dept Med Chem, Tehran, Iran

[2] Univ Tehran Med Sci, Drug Design & Dev Res Ctr, Tehran, Iran

[3] Univ Tehran, Dept Biochem, Inst Biochem & Biophys, Tehran, Iran

[4] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA

[5] Chapman Univ, Sch Pharm, Orange, CA 92866 USA

关键词: Antiproliferative activity;    Benzenesulfonamides;    Cancer;    Xanthone;   

DOI  :  10.1016/j.tetlet.2013.11.033

来源: Elsevier

【 摘 要 】

Several novel N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamide derivatives were prepared as potential antiproliferative agents. The in vitro antiproliferative activity of the synthesized compounds was investigated against a panel of tumor cell lines including breast cancer cell lines (MDA-MB-231, T-47D) and neuroblastoma cell line (SK-N-MC) using MTT colorimetric assay. Etoposide, a well-known anticancer drug, was used as a positive standard drug. Among synthesized compounds, 4-methoxy-N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamide (5i) showed the highest antiproliferative activity against MDA-MB-231, T-47D, and SK-N-MC cells. Furthermore, pentafluoro derivatives 5a and 6a exhibited higher antiproliferative activity than doxorubicin against human leukemia cell line (CCRF-CEM) and breast adenocarcinoma (MDA-MB-468) cells. Structure-activity relationship studies revealed that xanthone benzenesulfonamide hybrid compounds can be used for the development of new lead anticancer agents. (C) 2013 Elsevier Ltd. All rights reserved.

【 授权许可】

Free